Mar 26, 2024 8:00 am EDT Opus Genetics Announces Completion of Dosing in First Cohort of Phase 1/2 Trial of Gene Therapy OPGx-LCA5 in Patients with Rare Inherited Retinal Disease LCA5
Mar 8, 2024 8:00 am EST Ocuphire Pharma Announces Financial Results for Fourth Quarter and Full Year 2023 and Provides Corporate Update
Feb 15, 2024 4:10 pm EST Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Feb 5, 2024 8:00 am EST Ocuphire Pharma Announces Presentation on APX3330 at the Annual Angiogenesis, Exudation, and Degeneration 2024 Conference
Jan 24, 2024 4:10 pm EST Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jan 4, 2024 8:00 am EST Ocuphire Pharma Receives FDA Agreement Under Special Protocol Assessment for LYNX-2 Phase 3 Trial of Phentolamine Ophthalmic Solution for the Treatment of Decreased Visual Acuity under Dim (mesopic) Light Conditions
Nov 30, 2023 8:00 am EST Ocuphire Pharma Announces Presentation at Ophthalmology Innovation Summit (OIS) XIII
Nov 27, 2023 4:38 pm EST Ocuphire Pharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)